AMG National Trust Bank Has $2.68 Million Position in GSK PLC Sponsored ADR (NYSE:GSK)

AMG National Trust Bank increased its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 55.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,195 shares of the pharmaceutical company's stock after purchasing an additional 24,584 shares during the quarter. AMG National Trust Bank's holdings in GSK were worth $2,681,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Formidable Asset Management LLC lifted its holdings in GSK by 34.7% during the 1st quarter. Formidable Asset Management LLC now owns 9,349 shares of the pharmaceutical company's stock valued at $362,000 after purchasing an additional 2,407 shares during the last quarter. Nwam LLC lifted its holdings in GSK by 39.2% during the 1st quarter. Nwam LLC now owns 12,419 shares of the pharmaceutical company's stock valued at $481,000 after purchasing an additional 3,499 shares during the last quarter. Forum Financial Management LP increased its position in GSK by 3.0% in the 1st quarter. Forum Financial Management LP now owns 13,795 shares of the pharmaceutical company's stock valued at $534,000 after acquiring an additional 398 shares in the last quarter. Kooman & Associates acquired a new stake in GSK in the 1st quarter valued at about $221,000. Finally, Kingsview Wealth Management LLC increased its position in GSK by 1.8% in the 1st quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock valued at $590,000 after acquiring an additional 271 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Trading Down 0.3%

GSK stock traded down $0.11 during midday trading on Monday, hitting $36.21. 3,343,492 shares of the stock were exchanged, compared to its average volume of 5,099,963. The company has a fifty day simple moving average of $38.98 and a two-hundred day simple moving average of $37.43. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $44.67. The stock has a market capitalization of $74.12 billion, a PE ratio of 18.66, a P/E/G ratio of 1.47 and a beta of 0.50. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.05. GSK had a net margin of 9.89% and a return on equity of 48.82%. The firm had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. During the same quarter in the previous year, the firm posted $0.43 earnings per share. The business's revenue was up 2.1% on a year-over-year basis. Equities research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, July 10th. Stockholders of record on Friday, May 16th were given a $0.4216 dividend. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.66%. The ex-dividend date of this dividend was Friday, May 16th. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 88.14%.

Analysts Set New Price Targets

Several research firms have weighed in on GSK. BNP Paribas began coverage on shares of GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price objective for the company. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, Wall Street Zen cut shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, GSK presently has an average rating of "Hold" and a consensus target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.